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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: The prevalence of diabetes has increased worldwide. To obtain nation-
wide data on accountability and utilization of health resources among diabetes patients in
Taiwan, an analysis of the claims data for the National Health Insurance (NHI) from 2000 to
2009 was conducted.
Methods: One-third of the NHI claims database was randomly sampled from 2000 to 2009. Dia-
betes was defined by three or more outpatient visits with diagnostic codes [International Clas-
sification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM): 250 or A code: A181]
within 1 year, or one inpatient discharge diagnosis. Accountability items and NHI codes of
various metabolic parameters and examinations were identified. Medical utilization was
measured by the frequency and cost of care associated with ambulatory visits, hospitaliza-
tions, and emergency care within each year.
Results: The annual check-up frequency for various examinations significantly increased
from 2000 to 2009. Both the average outpatient department (OPD) cost per diabetes
patient/year and the average inpatient department (IPD) cost per time increased 1.34-fold
in the past decade. The average OPD cost per diabetes patient and average IPD cost of each
admission for diabetes patients was four times and 1.4 times compare with the general po-
pulation, respectively. The annual average medical cost of each diabetes patient affected
with both micro- and macrovascular complications was four times compared with those
without vascular complications. There was an increasing trend for diabetes patients to visitof Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan.
Diabetes Clinic, I-Lan, Taiwan.
ail.com (N.-C. Yu), leeming@ntu.edu.tw (L.-M. Chuang).
ight ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
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606 T.-J. Chang et al.regional hospital for OPD and IPD, whereas visits to the local hospital decreased in the past
decade.
Conclusion: Due to the increased frequency of annual check-ups after various examinations,
the quality of diabetes management has improved in the past decade in Taiwan. As diabetes
patients affected with both micro- and macrovascular complications incurred costs four
times compared with those without complications, it is worth screening high-risk individuals
to ensure earlier intervention and thus reduce diabetic complications and healthcare expen-
diture.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Diabetes mellitus (DM) has become a pandemic disorder
and this alarming increase in prevalence and the subse-
quent economic impact are both causes for significant
concern. It is estimated that more than 366 million people
worldwide suffer from diabetes, and this figure is expected
to increase to over 552 million by 2030.1,2 Type 2 diabetes
is also a big challenge to Asian societies, including Taiwan.3
In a recent analysis of Taiwan’s National Health Insurance
claims database, researchers found a universal increase in
the prevalence of type 2 diabetes for both men and
women, with the highest growth among those aged <40
years and >80 years from 1999 to 2004.4 Furthermore,
according to the nationwide survey of accredited Diabetes
Health Promotion Centers in Taiwan in 2006, the
percentage of DM patients who reached the American
Diabetes Association (ADA) goals, that is glycosylated
hemoglobin (A1C) <7% (A), blood pressure <130/80 mmHg
(B), total cholesterol (TCH) <160 mg/dL, or low-density
lipoprotein cholesterol level (LDLc) <100 mg/dL (C),
were 32.4%, 30.9%, and 35.3%, respectively. Overall, the
percentage of examined diabetes patients who fulfilled
current recommended ABC goals was only 4.1%.5
Studies have shown that diabetes complications can be
slowed or prevented by better management on the part of
health care teams and patients.6,7 To improve the quality
of diabetic care, Taiwan has established practice guide-
lines for diabetic care, implemented accreditation for
Diabetes Health Promotion Institutions, and set up shared
care networks in 25 counties.8 Professional accountability,
represented by adequacy of laboratory monitoring for
diabetic patients, is widely accepted as an indicator of
quality assessment for diabetes care in the process
domain.9e11 Moreover, with the increasing prevalence of
diabetes and accessibility of heath care resources at
different levels of health care providers in Taiwan, the
utilization of health resources in the treatment of diabetes
and its related complications has increased in past
decade.12
Only a few studies have reported the professional
accountability of diabetes care in Taiwan,13e16 and only
one has analyzed claims data from the NHI program in
2001,16 therefore, in this study, we used the Taiwan NHI
Database for the source population during 2000e2009 to
study the trend of accountability, utilization of health care
resources, and the distribution of different health care
providers for diabetes care in Taiwan during 2000e2009.Methods
Data source
A universal compulsory NHI program was launched by the
Taiwanese government in March 1995. It provided coverage
for 95% of the population in 2000, 98% of the population in
2005, and 99.6% of the total population of 23 million in
Taiwan in 2009. Although non-Chinese residents are also
eligible for this program, they only account for 1% of total
beneficiaries. Large computerized administrative and
claims data sets derived from this program have been
maintained on an ongoing basis by the National Health
Research Institute (NHRI) of Taiwan; these are made
available to investigators for research purposes after indi-
vidual health information has been de-identified. In this
study, inpatient and outpatient claims data sets for
2000e2009 were used.
Case selection
We searched the Taiwan NHI Database for the source pop-
ulation for 2000e2009 to identify any hospitalized event in
which diabetes was one of the discharge or outpatient
diagnostic codes (The International Classification of
Diseases, 9th Revision, Clinical Modification, ICD-9-CM code
250). The code A181 was used before June 2000 for
outpatients only. To protect patient privacy, the NHRI only
provided data for one-third of the randomly sampled
patients who were identified as having experienced
a hospitalized event or ambulatory visit for diabetes from
2000 to 2009. Patients were classified as having diabetes
and included in the analysis if they had at least one dia-
betes admission code or 3 outpatient codes within 365
calendar days. To avoid accumulation of misdiagnosis, we
used the selection method described for each year.
Outcome variable definitions
The outcome variables of chief interest were those related
to medical utilization associated with diabetes. The NHRI
database contained the following information: ambulatory,
emergency and hospitalization care files, including dates of
visits, medical care facilities; patients’ sex, date of birth;
the three to five diagnoses (ICD-9-CM); and the medical
expenses for each visit from all medical care institutions
under contract to the Bureau of National Health Insurance
Table 1 Annual check-up frequency for various metabolic parameters, electrocardiogram, fundus examination, nerve
conduction velocity and ankle-brachial index in Taiwan (2000e2009).
Parameters Annual
frequency
2000
(%)
2001
(%)
2002
(%)
2003
(%)
2004
(%)
2005
(%)
2006
(%)
2007
(%)
2008
(%)
2009
(%)
p for
trend
TCH 1 60.1 60.8 63.0 63.9 67.6 67.7 68.8 73.4 76.4 79.1 <0.001
TG 1 59.1 59.8 62.1 62.8 66.5 66.6 67.8 73.0 76.3 79.4 <0.001
LDLc 1 22.7 25.3 33.6 39.0 44.7 44.5 47.1 50.1 52.6 55.8 <0.001
HDLc 1 12.4 13.9 22.7 30.1 37.3 38.1 41.9 46.5 47.9 54.0 <0.001
LDLc or HDLc 1 23.4 26.5 35.3 41.5 48.0 48.7 52.5 58.3 62.6 67.9 <0.001
A1C 1 20.1 20.4 22.0 22.6 22.0 21.9 21.6 19.5 18.6 17.0 0.083
2 10.3 11.6 13.4 14.7 15.7 16.6 17.7 18.5 18.5 18.9 <0.001
3 6.1 7.8 9.5 10.7 12.2 13.4 14.9 16.5 17.3 19.0 <0.001
4 5.2 6.6 8.2 9.3 12.9 14.0 16.7 22.2 25.5 29.7 <0.001
Serum creatinine 1 62.9 64.6 67.2 68.2 71.4 71.3 72.0 74.2 77.7 82.0 <0.001
SGPT 1 56.8 58.2 62.2 64.2 68.5 68.1 68.9 71.1 72.3 75.3 <0.001
Urine routine 1 46.9 47.6 50.2 50.4 53.1 52.3 51.6 51.6 51.4 54.1 <0.001
Microalbuminuria 1 3.02 4.43 7.66 9.10 11.99 14.06 16.63 20.18 22.48 25.59 <0.001
Any urine 1 48.0 49.3 52.5 53.0 56.1 56.2 56.6 58.2 59.4 63.4 <0.001
Electrocardiogram 1 36.6 37.1 38.3 37.4 39.2 38.1 37.5 37.9 37.7 38.3 0.225
Fundus examination 1 16.0 17.7 21.4 22.8 25.3 26.0 25.5 24.9 25.2 28.2 <0.001
NCV 1 3.9 4.2 4.3 4.1 4.5 3.9 3.9 3.8 3.9 3.9 0.125
ABI 1 1.1 1.0 1.2 1.2 1.4 2.8 2.7 2.6 2.9 3.5 <0.001
ABIZ ankleebrachial index; A1CZ glycated hemoglobin; HDLcZ high-density lipoprotein cholesterol; LDLcZ low-density lipoprotein
cholesterol; NCV Z nerve conduction velocity; SGPT Z serum glutamic pyruvic transaminase; TCH Z total cholesterol;
TG Z triglyceride.
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frequency and cost of care associated with ambulatory
visits (including treatment with western medicine, tradi-
tional Chinese medicine, and dental visits, community
care, and home care). We also measured medical utiliza-
tion including hospitalization and emergency care within
each year. Only direct treatment costs (healthcare provider
costs) were investigated. All costs were reported in points
and under the global budget floating value system in which
1 point equaled 0.8635e0.9930 New Taiwan dollars (NT$)
from 2000 to 2009. In 2012, the exchange rate of the NT$
against the US dollar was 30 to 1.
The healthcare provider for diabetes management in
this study was measured by the annual number and
frequency in different hospital accreditation levels associ-
ated with ambulatory visits (including treatment with
western medicine and traditional Chinese medicine, and
dental visits, community care, and home care) and hospi-
talizations every year.
Accountability items and NHI codes were listed as follows:
(1) 09005: fasting plasma glucose or capillary blood sugar;Table 2 Annual check-up frequency for different parameter co
Parameters 2000
(%)
2001
(%)
2002
(%)
2003
(%)
A1C (2) þ LDLc or HDLc (1) 10.9 13.5 19.9 24.6
A1C (2) þ LDLc or HDLc (1)
þ Any Urine (1)
7.8 9.7 15.4 19.3
A1C (2) þ LDLc or HDLc (1)
þ Fundus examination (1)
3.3 4.5 8.5 11.2
A1C Z glycosylated hemoglobin; HDLc Z high-density lipoprotein ch(2) 09006: A1C; (3) 09001: total cholesterol (TCH); (4) 09004:
triglyceride (TG); (5) 09043: high-density lipoprotein choles-
terol (HDLc); (6) 09044: low-density lipoprotein cholesterol
(LDLc); (7) 09015: serum creatinine; (8) 09026: serum gluta-
mic pyruvic transaminase (SGPT or ALT); (9) 06012/06013:
urine protein; (10) 12111/27065: microalbuminuria; (11)
18001: electrocardiogram (ECG); (12) 23501/ 23502/ 23702:
eye fundus examination; (13) nerve conduction velocity
(NCV): 41145b, 20016b, 20019b; (14) ankle brachial index
(ABI): 18008b, 18008c, 18009a, 18009b, 18011a, 18011b.
Microvascular complications were defined as all types of
nephropathy and eye disease. Macrovascular complications
were defined as all types of cardiovascular disease, stroke
and peripheral vascular disease. These complications
defined with ICD-9, op and A-code: (1) all types of
nephropathy: 250.4, 403, 404, 585, 586, 581.8x, 791.0,
593.9, v42.0, v45.1, v56.0, v56.8, 39.27, 39.42, 39.43,
39.49, 39.50, 39.53, 39.93, 39.94, 39.95 (A350); (2) all types
of eye disease: 362.01, 362.02, 362.53, 362.83, 364.42,
379.23, 369.xx, 14.2x-14.5x, 14.7 (A232); (3) all types of
cardiovascular disease: 398.91, 402, 404, 410, 411, 412,mbinations in Taiwan (2000e2009).
2004
(%)
2005
(%)
2006
(%)
2007
(%)
2008
(%)
2009
(%)
p for
trend
30.7 32.5 36.8 44.3 48.7 55.3 <0.001
24.4 25.9 28.9 33.8 36.8 42.7 <0.001
14.3 15.1 15.8 17.0 17.9 21.5 <0.001
olesterol; LDLc Z low-density lipoprotein cholesterol.
able 3 DM medical benefit claims from outpatient service in Taiwan (2000e2009).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 p for
trend
M patient number (10,000) 70.7 74.8 81.3 86.8 94.5 100.0 105.5 112.8 120.5 122.3
M patients with OPD record (10,000 persons)
Total 70.5 74.6 81.1 86.5 94.1 99.6 105.2 112.5 120.1 121.9
Non-dialysis 69.5 73.5 79.8 85.0 92.4 97.7 103.0 110.0 117.3 119.0
Dialysis 1.0 1.1 1.3 1.5 1.7 1.9 2.2 2.5 2.8 2.9
verage OPD visit frequency per patienta
Total (FI)a 31.8
(2.16)
31.5
(2.18)
31.9
(2.19)
31.7
(2.21)
34.0
(2.20)
34.0
(2.20)
33.3
(2.27)
33.6
(2.27)
33.7
(2.26)
34.4
(2.22)
0.006
Non-dialysis (FI)a 31.7
(2.15)
31.5
(2.18)
31.8
(2.18)
31.6
(2.20)
33.9
(2.19)
33.8
(2.19)
33.1
(2.26)
33.4
(2.26)
33.4
(2.24)
34.1
(2.20)
0.017
Dialysis (FI)a 37.3
(2.53)
36.2
(2.53)
37.3
(2.56)
38.6
(2.69)
41.2
(2.67)
41.5
(2.69)
42.3
(2.88)
42.2
(2.85)
43.3
(2.90)
44.7
(2.88)
<0.001
PD cost (billion points)
Total 27.01 29.24 34.18 38.42 44.96 47.42 50.92 54.93 59.86 62.75
Non-dialysis 22.83 24.50 28.63 31.68 37.24 38.95 40.59 43.27 46.76 48.76
Dialysis 4.18 4.74 5.55 6.74 7.72 8.47 10.32 11.65 13.11 13.99
verage OPD cost per patientb
Total (FI)b 38,298
(4.13)
39,206
(4.10)
42,143
(4.11)
44,381
(4.15)
47,744
(3.97)
47,599
(3.88)
48,402
(3.92)
48,823
(3.85)
49,829
(3.72)
51,456
(3.63)
<0.001
(<0.001)
Non-dialysis (FI)b 32,858
(3.54)
33,362
(3.49)
35,888
(3.50)
37,255
(3.49)
40,293
(3.35)
39,859
(3.25)
39,406
(3.19)
39,349
(3.10)
39,851
(2.98)
40,982
(2.89)
0.001
(<0.001)
Dialysis (FI)b 398,651
(42.98)
415,730
(43.38)
415,194
(40.51)
437,392
(40.93)
444,219
(36.97)
444,111
(36.23)
472,528
(38.28)
461,136
(36.37)
466,739
(34.85)
472,127
(33.31)
<0.001
(<0.001)
PD drug cost (billion points)
Total 11.47 12.37 14.52 16.23 19.12 19.35 20.61 21.54 23.27 23.99
Non-dialysis 11.20 12.08 14.15 15.78 18.60 18.78 19.83 20.59 22.11 22.71
Dialysis 0.27 0.29 0.37 0.46 0.52 0.57 0.78 0.95 1.16 1.28
verage drug cost per patientc
Total 16,266 16,590 17,900 18,751 20,305 19,417 19,590 19,149 19,368 19,675 0.007
Non-dialysis 16,123 16,452 17734 18,554 20,120 19,216 19,246 18,722 18,844 19,087 0.020
Dialysis 25,713 25,439 27819 29,585 30,157 29,727 35,813 37,696 41,264 43,314 <0.001
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Accountability, utilization and providers for diabetes management 609413, 414, 428, 36.xx, (A260, A27, A270, A25, A250, A251);
(4) all types of stroke: 430, 431, 432, 433, 434, 435, 436,
785.9 (A290eA294); (5) all types of peripheral vascular
disease: 440.2x, 443.9, 84.1x, 39.25, 39.29, 39.50, 39.59
(A300, A301, A302).
Statistical analysis
We performed the trend tests to examine linear gradient
relationship with the risk of endpoints of interest. All
statistical analyses were performed with the SAS version
9.1 (SAS Institute, Cary, NC, USA). A p value <0.05 was
considered to be statistically significant.
Results
Annual frequency of checks for various metabolic
parameters increases gradually
As shown in Table 1, the annual percentage of diabetes
patients undergoing lipid profile checks (including LDLc and
HDLc), serum creatinine, SGPT, and any urine analysis (i.e.,
urine routine or microalbuminuria) increased significantly
from 2000 to 2009. The percentage of patients who
underwent checks for A1C levels more than twice annually
and annual rate for fundus examination also significantly
rose from 21.6% and 16.0% in 2000 to 67.6% and 28.2% in
2009, respectively. The annual check-up rate of electro-
cardiogram remained stable (approximately one-third) over
the 10-year period.
Along with improved quality of diabetes management,
the annual check-up rate for combinations of A1C, LDLc or
HDLc, or any urine analysis, or fundus examination signifi-
cantly increased from 2000 to 2009 (Table 2).
DM patient utilization of outpatient service from
2000 to 2009
The total number of all diabetes patients visiting OPDs
increased from 2000 to 2009. More prominently, the
number of dialysis diabetes patients visiting the OPD
dramatically increased from 10,000 in 2000 to 29,000 in
2009; this was an increase of 182.5% (Table 3). The average
annual OPD visit frequency, OPD cost and drug cost for each
diabetes patient also increased significantly from 2000 to
2009. The average annual OPD visit frequency was about
2.2 times as high as that for the whole population. The ratio
was much higher for dialysis patients and significantly
increased from 2.53 times in 2000 to 2.88 times in 2009.
However, the ratio of average annual OPD cost between
diabetes patients and the whole population significantly
decreased in the past decade. For all diabetes patients and
non-dialysis diabetes patients, the percentages of OPD
drug cost to total OPD cost decreased significantly from
2000 to 2009. Conversely, for dialysis diabetes patients, the
ratio significantly increased by 42.2%. The percentage of
DM OPD costs in relation to the whole population OPD cost
also significantly increased by 48.0%, 35.8% and 115.8% for
all diabetes patients, non-dialysis diabetes patients and
dialysis diabetes patients, respectively.
610 T.-J. Chang et al.DM patient utilization of inpatient service from
2000 to 2009
As shown in Table 4, the total number of diabetes patients
ever hospitalized increased from 2000 to 2009. More
prominently, the number of dialysis diabetes patients ever
hospitalized dramatically increased from 8900 in 2000 to
22,100 in 2009; a 148.5% increase. The total annual IPD cost
and IPD drug cost, average IPD cost and average hospital
days for each hospitalization also significantly increased
from 2000 to 2009. The percentage of IPD drug costs to total
IPD costs significantly decreased by 16.3%, 16.3% and 8.2%
from 2000 to 2009 in all diabetes patients, non-dialysis
diabetes patients, and dialysis diabetes patients, respec-
tively. The percentage of DM IPD cost to the whole pop-
ulation IPD cost also significantly increased by 36.8%, 29.2%
and 95.5% from 2000 to 2009 for all diabetes patients, non-
dialysis diabetes patients, and dialysis diabetes patients,
respectively.
Etiology of expense in OPD and IPD from 2000 to
2009
We further analyzed OPD and IPD expenditure from 2000 to
2009. The first ranked etiology in terms of expense in OPD
comprised endocrine, nutritional and metabolic disease
and immune disorders (ICD-9-CM: 240-279) but the
percentage decreased significantly from 2000 to 2009. The
second ranked etiology in terms of OPD expenditure was
diseases of the genitourinary system (ICD-9-CM: 580-629)
and this percentage increased significantly from 2000 to
2009. The third highest etiology for OPD expense was
diseases of circulatory system (ICD-9-CM: 390-459); this
decreased significantly in this study period, which can be
attributed to the significantly decreased percentage of
hypertension form 2000 to 2009. The percentages for
ischemic heart disease and cerebrovascular disease
remained consistent in the past decade. In 2000, the top
three etiologies in terms of IPD expenditure were diseases
of the circulatory system (22.50%), disease of the respira-
tory system (15.43%) and endocrine, nutritional, metabolic
disease and immune disorders (9.32%). However, since
2004, the top three etiologies for IPD expenditure have
been diseases of the respiratory system (24.47%), diseases
of the circulatory system (20.62%), and neoplasms (8.54%;
Table 5). From 2000 to 2009, the percentage of IPD costs
dedicated to diseases of the respiratory system and infec-
tious and parasitic diseases significantly increased. By
contrast, during the past decade the percentage of IPD
costs dedicated to diseases of the circulatory system,
diseases of the digestive system, injury and poisoning, and
diseases of the genitourinary system as well as endocrine,
nutritional and metabolic diseases and immune disorders,
and diseases of the musculoskeletal system and connective
tissue all decreased significantly (Table 5).
Medical costs for diabetic patients with/without
complications
In this study, we further analyzed the medical costs for
diabetic patients with or without either microvascular ormacrovascular complications. As shown in Table 6, the
percentage of diabetes patients without complications
remained consistent at w49% from 2000 to 2009. However,
the percentage of diabetes patients with microvascular
complications significantly increased by 45.3% from 2000 to
2009. By contrast, the percentage of diabetes patients with
macrovascular complications significantly decreased by
13.5% from 2000 to 2009. The percentage of diabetes
patients with both macro- and microvascular complications
slightly increased from 10.0% in 2000 to 11% in 2009
(p Z 0.121). The average annual cost also significantly
increased by 34.2%, 19.0%, 27.6% and 33.1% from 2000 to
2009 in diabetes patients without any complications, with
microvascular complications, with macrovascular compli-
cations and with both micro- and macrovascular complica-
tions, respectively. The average annual cost for each
diabetes patient was about two times higher in diabetes
patients with either micro- or macrovascular complications
compared with those without any complications. The
average annual cost for diabetes patients with both micro-
and macrovascular complications was about four times
higher compared with those without any complications.
Distribution of inpatient and outpatient services at
diabetes health care institutions
As shown in Fig. 1A, about 30% of diabetes patients visited
OPD at clinics, and there was an increasing trend towards
visiting regional hospitals from 2000 to 2009, with an
increase of 18.8%. Conversely, there was a decreasing trend
towards visiting medical centers and local hospitals from
2000 to 2009 with a decrease of 12.2% and 21.3%, respec-
tively. As shown in Fig. 1B, about 30% of diabetes patients
used the IPD at medical centers. There was an increasing
trend towards hospitalization at regional hospitals from
2000 to 2009, with an increase of 25.1%. There was
a decreasing trend for hospitalization at local hospitals
from 2000 to 2009, with a decrease of 38%.
Discussion
In the present study we used the Taiwan National Health
Insurance Database for the source population from 2000 to
2009 to study trends in diabetes care in terms of account-
ability and utilization of health care resources and
providers in the past decade. We found that accountability
in terms of measurement of lipid profile, A1C, screening for
nephropathy, liver function tests, fundus examinations, and
ABI increased significantly in the past decades. Both the
annual OPD and IPD costs for diabetes patients also
increased significantly in this period. However, the average
IPD cost for each period of hospitalization compared with
the general population decreased gradually from 1.41 times
as high as that in 2005 to 1.37 times as high as that in 2009.
The main etiology for OPD expenditure consisted of endo-
crine, nutritional and metabolic disease and immune
disorders, and the chief etiology for IPD expenditure was
diseases of the circulatory system in 2000. However, this
changed to respiratory disease from 2004 onwards.
Tseng et al analyzed the claims data from the Taipei
Branch of the NHI program in 2001 and reported that the
Table 4 DM medical benefit claims from in patient service in Taiwan (2000e2009).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 p for trend
DM patient number (10,000) 70.7 74.8 81.3 86.8 94.5 100.0 105.5 112.8 120.5 122.3
DM patients with IPD record (10,000)
Total 20.02 20.84 22.85 22.89 25.63 26.25 26.57 28.09 29.49 30.47
Non-dialysis 19.13 19.86 21.72 21.64 24.22 24.72 24.93 26.18 27.39 28.26
Dialysis 0.89 0.97 1.13 1.25 1.41 1.53 1.64 1.91 2.10 2.21
IPD cost (billion points)
Total 20.05 21.96 26.06 28.00 34.76 36.88 36.86 39.21 42.07 44.12
Non-dialysis 17.76 19.46 23.05 24.46 30.27 31.88 31.91 33.09 35.33 36.94
Dialysis 2.29 2.50 3.01 3.54 4.49 5.00 4.95 6.12 6.74 7.18
IPD drug cost (billion points)
Total 3.49 3.58 4.27 4.45 5.60 5.92 5.81 5.91 6.30 6.44
Non-dialysis 3.18 3.25 3.87 4.00 4.99 5.27 5.17 5.13 5.41 5.53
Dialysis 0.31 0.33 0.40 0.45 0.61 0.65 0.64 0.78 0.89 0.90
IPD drug cost/IPD cost
Total 17.4% 16.3% 16.4% 15.9% 16.1% 16.0% 15.8% 15.1% 15.0% 14.6% <0.001
Non-dialysis 17.9% 16.7% 16.8% 16.4% 16.5% 16.5% 16.2% 15.5% 15.3% 15.0% <0.001
Dialysis 13.7% 13.1% 13.2% 12.8% 13.5% 13.0% 12.9% 12.8% 13.2% 12.6% 0.055
Average IPD cost/time
Total (FI) 52,561
(1.44)
53,902
(1.45)
57,421
(1.47)
62,224
(1.44)
67,091
(1.43)
69,223
(1.41)
69,087
(1.38)
69,481
(1.38)
70,148
(1.36)
70,518
(1.37)
<0.001
(<0.001)
Non-dialysis (FI) 49,911
(1.37)
51,286
(1.38)
54,703
(1.40)
58,979
(1.36)
63,365
(1.35)
65,226
(1.33)
65,324
(1.30)
64,698
(1.29)
65,294
(1.29)
65,562
(1.27)
<0.001
(<0.001)
Dialysis (FI) 89,427
(2.45)
89,351
(2.40)
92,721
(2.37)
100,402
(2.32)
111,124
(2.37)
113,595
(2.31)
109,899
(2.20)
115,747
(2.30)
114,881
(2.23)
115,403
(2.24)
<0.001
(0.001)
Average Hospital days/time
Total (FI) 10.8
(1.24)
10.9
(1.23)
11.2
(1.24)
11.6
(1.20)
11.9
(1.23)
12.0
(1.22)
11.9
(1.20)
11.8
(1.18)
11.9
(1.16)
11.9
(1.17)
(0.001)
Non-dialysis (FI) 10.6
(1.22)
10.7
(1.21)
11.0
(1.22)
11.4
(1.18)
11.6
(1.20)
11.7
(1.19)
11.7
(1.18)
11.5
(1.15)
11.6
(1.13)
11.7
(1.15)
(0.005)
Dialysis (FI) 13.7
(1.57)
13.7
(1.55)
13.5
(1.49)
14.2
(1.47)
16.1
(1.66)
14.8
(1.50)
14.2
(1.43)
14.5
(1.45)
14.3
(1.39)
14.2
(1.40)
(0.028)
DM IPD Cost/whole population IPD cost
Total 19.3% 19.9% 21.4% 23.1% 23.5% 24.0% 24.0% 24.8% 25.5% 26.4% <0.001
Non-dialysis 17.1% 17.6% 18.9% 20.2% 20.5% 20.8% 20.8% 20.9% 21.4% 22.1% <0.001
Dialysis 2.2% 2.3% 2.5% 2.9% 3.0% 3.2% 3.2% 3.9% 4.1% 4.3% <0.001
DM Z diabetes mellitus; FI Z fold increase compared with whole population in index year; IPD Z inpatient service.
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Table 5 DM medical benefit claims analysis according to classification of diseases in Taiwan (2000e2009).
Classification of diseases (Cost % in OPD) 2000
(%)
2001
(%)
2002
(%)
2003
(%)
2004
(%)
2005
(%)
2006
(%)
2007
(%)
2008
(%)
2009
(%)
p for
trend
Endocrine, nutritional and metabolic
diseases and immunity disorders
26.39 26.22 26.39 26.70 26.77 26.18 25.79 24.96 24.39 24.34 0.008
Diseases of the genitourinary system 17.91 18.89 18.87 19.58 19.12 20.04 20.83 21.92 22.66 23.11 0.001
Diseases of the circulatory system 15.97 16.26 16.72 16.62 16.42 15.82 15.81 15.30 14.89 14.26 0.004
Hypertension 8.27 8.12 7.98 7.72 7.73 7.25 7.02 6.80 6.60 6.30 0.001
Ischemic heart disease 2.37 2.60 2.72 2.86 2.80 2.71 2.84 2.70 2.60 2.50 0.764
Cerebrovascular disease 3.84 4.02 4.47 4.60 4.42 4.39 4.44 4.30 4.20 4.10 0.629
Others 1.48 1.52 1.54 1.44 1.46 1.46 1.52 1.50 1.50 1.40 0.317
Diseases of the digestive system 7.64 7.36 7.06 6.69 6.75 6.48 6.34 6.30 6.12 6.04 0.001
Neoplasms 3.43 6.18 2.66 3.93 4.09 4.60 5.05 5.58 6.00 6.27 0.051
Diseases of the musculoskeletal system
and connective tissue
5.45 5.31 5.79 5.63 5.84 5.58 5.50 5.34 5.45 5.46 0.598
Diseases of the nervous system and
sense organs
6.19 4.97 5.96 5.53 5.50 5.37 5.21 5.09 5.00 4.96 0.023
Others 17.03 14.82 16.56 15.30 15.51 15.94 15.47 15.51 15.49 15.55 0.291
Cost in IPD
Diseases of the respiratory system 15.43 17.38 19.63 22.58 24.47 25.26 23.69 24.13 23.49 23.98 0.005
Pneumonia and influenza 5.24 5.69 6.27 6.64 6.71 7.36 6.68 7.26 7.02 7.26 0.001
Respiratory failures and other
pulmonary disease
4.53 5.77 8.22 10.97 12.94 13.08 12.53 13.17 12.60 13.17 0.001
Others 5.66 5.91 5.14 4.97 4.82 4.82 4.48 3.70 3.87 3.55 0.001
Diseases of the circulatory system 22.50 22.43 21.28 20.57 20.62 20.15 20.33 20.06 20.29 20.06 0.001
Ischemic heart disease 8.89 9.07 8.76 8.60 8.52 8.28 8.15 8.50 8.50 8.30 0.007
Cerebrovascular disease 7.63 8.02 7.44 6.97 6.48 6.35 6.30 5.70 5.80 5.60 0.001
Others 5.97 5.35 5.09 5.00 5.62 5.52 5.88 5.86 6.00 6.20 0.072
Neoplasms 9.02 9.52 8.91 8.60 8.54 8.76 9.01 9.11 9.26 9.69 0.354
Diseases of the digestive system 9.31 9.51 8.97 8.66 8.24 7.53 7.53 7.80 7.63 7.15 0.001
Injury and poisoning 7.94 7.75 7.27 7.36 6.87 7.10 7.17 6.71 7.04 7.04 0.007
Infectious and parasitic diseases 3.39 3.52 3.54 3.58 4.22 4.76 5.37 5.49 5.47 5.57 0.001
Disease of the genitourinary system 8.13 8.03 7.22 6.72 6.18 5.59 5.55 5.26 5.36 5.19 0.001
Endocrine, nutritional and metabolic
diseases and immunity disorders
9.32 8.51 7.73 7.28 6.43 5.99 5.34 5.26 4.80 4.45 0.001
Diseases of the musculoskeletal system
and connective tissue
8.13 8.03 7.22 6.72 6.18 5.59 5.55 5.26 5.36 5.19 0.001
IPD Z inpatient service; OPD Z outpatient service.
612 T.-J. Chang et al.percentages of patients who had undergone measurements
in that year for plasma glucose, A1C, urinalysis, renal
function tests, lipid profile, liver function tests, and fundus
examinations were 76.3%, 42.7%, 40.2%, 59.7%, 59.2%,
53.2%, and 16.8%, respectively.16 These accountability data
were similar to our data from 2001. From this, we can infer
that the methods and analysis used in our study are reli-
able. According to the accountability measures of diabetes
care reported by BNHI, the percentages of patients who
received measurements from 2004 to 2009 for A1C, lipid
profile, microalbuminuria and fundus examination were
also compatible with our present results.17 According to
Diabetes Quality Improvement Project (DQIP) account-
ability measures from 1994 to 1999, the baseline and final
frequencies for lipid testing, A1C, dilated eye examination,
and screening for diabetic nephropathy were as follows:
13e50%, 37e69%, 30e46%, and 37e50%, respectively.9
Compared with DQIP from 1994 to 1999, the annual rates
of fundus examination and microalbuminuria remained toolow in Taiwan, even in 2009; thus there is still much room to
improve annual check-up rates for fundus examination and
microalbuminuria. Diabetic retinopathy is one of the fast-
est growing causes of blindness and visual impairment in
the working-age population.18 However, most diabetic
patients may not experience any warning symptoms during
the early stage of retinopathy.18 Therefore, fundus exami-
nation (direct and indirect ophthalmoscopy) is an important
screening tool for early detection.
The authors of a recent study analyzing the NHI claims
database found a universal increase in the prevalence of
type 2 diabetes4; therefore, the OPD and IPD medical costs
directed towards diabetes patients also saw large increases
in the past decade in Taiwan; this was especially true for
diabetes patients receiving dialysis, for whom costs
increased 234.5% and 213.7% for OPD and IPD, respectively.
The average annual OPD and IPD cost for each diabetes
patient also significantly increased in the past decade. For
OPD patients, these increases were 34.4% for all diabetes
Table 6 Medical costs for DM patients with/without complications in Taiwan, 2000e2009.
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 p for trend
DM patient number
(10,000)
70.7 74.8 81.3 86.8 94.5 100.0 105.5 112.8 120.5 122.3
Without
complications
(10,000) (%)
34.7 (49.1%) 36.6 (49.0%) 39.8 (48.9%) 42.8 (49.3%) 46.4 (49.1%) 48.8 (48.9%) 52.1 (49.4%) 55.9 (49.6%) 60.0 (49.8%) 60.2 (49.2%) (0.055)
With microvascular
complications
(10,000) (%)
5.3 (7.5%) 6.1 (8.2%) 7.2 (8.8%) 7.7 (8.9%) 8.7 (9.3%) 9.6 (9.6%) 10.2 (9.7%) 11.1 (9.8%) 12.2 (10.2%) 13.3 (10.9%) (<0.001)
With macrovascular
complications
(10,000) (%)
23.6 (33.4%) 24.4 (32.6%) 25.9 (31.8%) 27.3 (31.4%) 29.1 (30.8%) 30.7 (30.7%) 32.0 (30.3%) 33.8 (30%) 35.4 (29.4%) 35.3 (28.9%) (<0.001)
With macro- and
microvascular
complications
(10,000) (%)
7.1 (10.0%) 7.6 (10.2%) 8.5 (10.5%) 9.0 (10.4%) 10.2 (10.8%) 10.8 (10.8%) 11.2 (10.6%) 12.0 (10.6%) 12.8 (10.6%) 13.4 (11%) (0.121)
Average annual cost (10,000 points)/patient
Without
complications
3.8 3.8 4.2 4.3 4.8 4.8 4.7 4.7 4.9 5.1 <0.001
With microvascular
complications (FI)
8.4 (2.21) 8.6 (2.26) 8.9 (2.12) 9.5 (2.21) 10.1 (2.10) 10.0 (2.08) 10.1 (2.15) 10.0 (2.13) 10.1 (2.06) 10.0 (1.96) 0.001 (0.005)
With macrovascular
complications (FI)
7.6 (2.00) 7.7 (2.03) 8.7 (2.07) 8.9 (2.07) 9.8 (2.04) 9.7 (2.02) 9.4 (2.00) 9.3 (1.98) 9.4 (1.92) 9.7 (1.90) 0.005 (0.012)
With macro- and
microvascular
complications (FI)
16.0 (4.21) 16.2 (4.26) 17.2 (4.10) 18.2 (4.23) 19.7 (4.10) 20.0 (4.17) 20.2 (4.30) 20.8 (4.43) 21.1 (4.31) 21.3 (4.18) <0.001 (0.301)
DM Z diabetes mellitus; FI Z fold increase compared with DM patients without complications in index year.
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Figure 1 Distribution of different health care institutions for total diabetes patients (2000e2009) at (A) outpatient service
and (B) inpatient service.
614 T.-J. Chang et al.patients, 24.7% for non-dialysis diabetes patients, and
28.4% for dialysis diabetes patients. For IPD patients, these
increases were 34.2%, 34.2%, and 29% for the all diabetes,
non-dialysis diabetes, and dialysis diabetes groups,
respectively. Compared with the general population, the
average annual OPD cost for each diabetes patient was 2.89
and 33.31 times as high as that in 2009 in non-dialysis and
dialysis diabetes patients, respectively. The frequency of
OPD visits was also much higher in diabetes patients than
for the general population, especially among diabetes
patients receiving dialysis. In 2009, the rate of visits for
non-dialysis patients was 2.20 times as high as that in the
general population, and the rate for dialysis patients was
2.88 times as high as that for the general population. One
recent study reported that progression of nephropathy was
strongly associated with higher subsequent medical care
costs in hypertensive patients with diabetes.19 A Canadian
study has reported that population-based screening for
chronic kidney disease with assessment of estimated
glomerular filtration rate is not cost-effective overall or in
subgroups of people with hypertension or older people.However, targeted screening of people with diabetes is
associated with a cost per quality-adjusted life years
(QALY) that is similar to that accepted in other interven-
tions funded by public healthcare systems, and is within
a range that is generally considered acceptable.20 There-
fore, early detection of and intervention for chronic kidney
disease in diabetes patients was a critical issue in
decreasing the burden on the health care system.
The medical costs of OPD for diabetes care accounted
for approximately 12.5% of all OPD expenditure in Taiwan in
2000, and this significantly increased to 18.5% in 2009.
Similarly, the medical costs of IPD for diabetes care
accounted for approximately 19.3% of total IPD cost in 2000
and significantly increased to 26.4% in 2009. According to
the health economic data from the UK, diabetes accounted
for approximately 10% of the total health resource expen-
diture in 2011.21 The higher prevalence of diabetes in
Taiwan (9.59%, age 20e79 years)1 compared with the UK
(6.84%, age 20e79 years)1 may explain the fact that dia-
betes care comprises a higher percentage of medical
resources expenditure in Taiwan. Therefore, prevention of
Accountability, utilization and providers for diabetes management 615diabetes is an important issue in national health policy in
Taiwan in terms of reducing both the economic and health
burdens. In the present study, we also found that medical
costs for diabetes patients with either microvascular or
macrovascular complications were approximately twice as
high as those for patients who had no complications.
Furthermore, for the diabetes patients with both
microvascular and macrovascular complications, medical
expenses dramatically increased to four times as high as
those for diabetes patients without any complications.
Therefore, an increase in efforts to improve the quality of
diabetes care and decrease the complication rate is
mandatory in Taiwan because this will decrease the health
economic burden for both individuals and the nation.
As shown in Table 6, the percentage of diabetes patients
with microvascular complications alone was lower than in
those who have both micro- and macrovascular complica-
tions. According to NHI claims data in the present study,
about half of diabetes patients with defined microvascular
complications (i.e., all types of eye disease and kidney
disease) had concomitant defined macrovascular compli-
cations (i.e., all types of cardiovascular disease, stroke and
peripheral vascular disease). By contrast, only about 27% of
diabetes patients with defined macrovascular complica-
tions had concomitant defined microvascular complications
(data not shown). It may explain why the percentage of
diabetes patients with macrovascular complications alone
was the highest among all diabetes patients, and the
percentage of those who have microvascular complications
alone was the lowest among all diabetes patients. The
average annual cost for each diabetes patient with micro-
vascular complications alone was slightly higher than in
those who had macrovascular complications alone, which
maybe explained that the medical expenditure for diabetes
patients receiving dialysis (classified as microvascular
complications) was about 11 times and 1.7 times as high as
those for the non-dialysis diabetes patients at the OPD and
IPD, respectively (Tables 3 and 4).
In this study, we found that the average medical cost
ratio between diabetes and non-diabetes patients signifi-
cantly decreased for both non-dialysis and dialysis diabetes
patients in the period 2000e2009. These trends may be
partially explained by earlier detection of diabetes after
nationwide health insurance implementation in 1994.
Before this implementation, the undiagnosed rate of dia-
betes was roughly 50%,22 but the undiagnosed rate of dia-
betes has now decreased to around 30% according to claims
data from the NHI and the 5th International Diabetes
Federation (IDF) atlas.1
The top three etiologies in terms of OPD expenditure
were endocrine, nutritional and metabolic disease and
immune disorders; diseases of the genitourinary system;
and diseases of the circulatory system. The percentage of
OPD expenditure dedicated to endocrine, nutritional, and
metabolic disease and immune disorders; and diseases of
the circulatory diseases significantly decreased in the past
decade. However, the percentage of OPD expenditure given
over to diseases of the genitourinary system significantly
increased in that period. In 2000, the top three etiologies
for IPD expenditure were diseases of the circulatory
system, disease of the respiratory system and endocrine,
nutritional, metabolic disease and immune disorders in2000. Conversely, the top three etiologies of IPD expense
shifted to disease of the respiratory system, diseases of the
circulatory system, and neoplasms from 2004 onwards (see
Table 5). During the past decade, the percentage of IPD
costs dedicated to the treatment of diseases of the respi-
ratory system, and infectious and parasitic diseases saw
a significant increase. By contrast, significant IPD cost
decreases were seen in the past decade for the following:
diseases of the circulating system; diseases of the digestive
system; injury and poisoning; diseases of the genitourinary
system; endocrine, nutritional and metabolic diseases and
immune disorders; and diseases of the musculoskeletal
system and connective tissue. According to the analysis of
Taiwan NHI claims data, the overall incidence of diabetic
ketoacidosis also linearly decreased between 1997 and
2005.23 The change in disease pattern in diabetes patients
provided important information for the implementation of
health policy in Taiwan.
One Taiwan-based study has highlighted the importance
of considering the level of the major care unit and the
frequency of visits for each patient for research into the
accountability of diabetes care.16 In this study, we found
that diabetes patients were increasingly likely to visit the
OPD in regional hospitals, whereas the utilization of
medical centers and local hospitals decreased in the past
decade. Similarly, there was an increasing trend towards
hospitalization at regional hospitals and a decrease in
hospitalization in local hospitals. Whether these change
influenced the quality of care and outcome of diabetes
patients needs further investigation.
In conclusion, the frequency of annual examinations for
various metabolic parameters for diabetes patients
increased gradually from 2000 to 2009; this indicates an
improvement in the quality of diabetes management in
Taiwan. However, diabetes mellitus patients with both
microvascular and macrovascular complications place
a large financial burden on the healthcare system. There-
fore, it is worth screening high-risk individuals for earlier
intervention to reduce diabetic complications and health-
care expenditure. At the same time, the change of disease
pattern in diabetes patients in the past decade provides
important information for the implementation of health
policy in Taiwan.
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